Few regulatory issues have the potential to reshape pharmaceutical manufacturing as profoundly as PFAS. Often referred to as "forever chemicals", per- and polyfluoro...

Typically, global companies developing innovative therapies are familiar with the differences between regulatory systems in the United States and European Union. In ...

The EU’s Health Technology Assessment Regulation (EU-HTAR) aims to introduce more harmonised, efficient and evidencebased assessments of new health technologies. How...

Patient centricity has become one of the most widely shared ambitions in clinical research. The industry increasingly recognises that engaging patients early in deve...

The global skincare market represents a multi-hundred-billion-dollar industry, with continued growth projected over the coming decade. A significant portion of this ...

Driven by complex modalities, global supply chains, and strategic partnerships, increased outsourcing makes tech transfer a critical process for both CDMOs and spons...